Drug Information

Drug General Information
Drug ID
D09ZWH
Former ID
DNCL001664
Drug Name
LX2931
Drug Type
Small molecular drug
Indication Rheumatoid arthritis [ICD9: 710-719, 714; ICD10:M05-M06] Phase 2 [522666]
Company
Lexicon Pharmaceuticals
Structure
Download
2D MOL

3D MOL
Formula
C9H15N3O5
Canonical SMILES
CC(=C1NC=C(N1)C(C(C(CO)O)O)O)N=O
InChI
1S/C9H15N3O5/c1-4(12-17)9-10-2-5(11-9)7(15)8(16)6(14)3-13/h2,6-8,10-11,13-16H,3H2,1H3/b9-4-/t6-,7-,8-/m1/s1
InChIKey
CGJLPLVZAAEKTK-LQGQQNNSSA-N
PubChem Compound ID
46926352
PubChem Substance ID
99431619, 140424176, 141227256, 226644875, 226644877
Target and Pathway
Target(s) Sphingosine 1 phosphate lyase 1 Target Info Inhibitor [531468], [532456]
KEGG Pathway Sphingolipid metabolism
Metabolic pathways
Sphingolipid signaling pathway
Pathway Interaction Database Sphingosine 1-phosphate (S1P) pathway
PathWhiz Pathway Sphingolipid Metabolism
Reactome Sphingolipid de novo biosynthesis
WikiPathways Sphingolipid metabolism
References
Ref 522666ClinicalTrials.gov (NCT00903383) Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotrexate. U.S. National Institutes of Health.
Ref 531468S1P is associated with protection in human and experimental cerebral malaria. Mol Med. 2011;17(7-8):717-25.
Ref 532456Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.